Alzheimer's Disease
Conditions
Keywords
Alzheimer disease
Brief summary
The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy subjects.
Detailed description
The overall research questions to be addressed by this protocol are as follows: * To assess the dynamic uptake and washout of (123I) MNI-168, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in Alzheimer's (AD) subjects and similarly aged and gender matched healthy controls. * To perform blood metabolite characterization of (123I) MNI-168 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of (123I) MNI-168 as a single photon computed tomography (SPECT) brain imaging agent. * To acquire initial safety data following injection of (123I) MNI-168. * Obtain test/retest reproducibility information in AD subjects with (123I) MNI-168 based on initial studies.
Interventions
DRUGI-123-MNI-168
Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
DRUG123-I MNI-168
Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Sponsors
Institute for Neurodegenerative Disorders
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects who have a clinical diagnosis of AD will be recruited for this study * The participant is 50 years or older * Written informed consent is obtained * Participants have a clinical diagnosis of probable Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria * Subjects will have a clinical dementia rating (CDR) assessment score of ≥ 0.5 and \< 2.0 * Modified Hachinski Ischemia Scale score of ≤ 4 * For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-168 injection
Exclusion criteria
* The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease * The subject has clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness * The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery) * The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease * The subject has participated in another clinical study within the previous 30 days * Clinically significant MRI evidence of vascular disease or alternative neurologic disorder * Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for β-amyloid burden in brain, | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| To acquire initial safety data following injection of (123I) MNI-168. | 1 year |
Countries
United States
Outcome results
None listed